GlycoMimetics: NCI Phase 2/3 study of uproleselan did not meet primary endpoint
PremiumThe FlyGlycoMimetics: NCI Phase 2/3 study of uproleselan did not meet primary endpoint
5d ago
GlycoMimetics Announces Strategic Review and Restructuring Plan
Premium
Company Announcements
GlycoMimetics Announces Strategic Review and Restructuring Plan
3M ago
GLYC Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
GLYC Earnings this Week: How Will it Perform?
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
4M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
GlycoMimetics Reports Phase 3 Uproleselan Trial Success
Premium
Company Announcements
GlycoMimetics Reports Phase 3 Uproleselan Trial Success
5M ago
GlycoMimetics Announces Promising Phase 3 Leukemia Drug Results
PremiumCompany AnnouncementsGlycoMimetics Announces Promising Phase 3 Leukemia Drug Results
6M ago
GlycoMimetics downgraded to Equalweight from Overweight at Capital One
Premium
The Fly
GlycoMimetics downgraded to Equalweight from Overweight at Capital One
6M ago
GlycoMimetics downgraded at H.C. Wainwright after AML trial misses endpoint
Premium
The Fly
GlycoMimetics downgraded at H.C. Wainwright after AML trial misses endpoint
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100